TY - JOUR
T1 - A comprehensive treatment for peritoneal metastases from gastric cancer with curative intent
AU - Yonemura, Y
AU - Canbay, E
AU - Li, Y
AU - Coccolini, F
AU - Glehen, O
AU - Sugarbaker, P H
AU - Morris, D
AU - Moran, B
AU - Gonzaletz-Moreno, S
AU - Deraco, M
AU - Piso, P
AU - Elias, D
AU - Batlett, D
AU - Ishibashi, H
AU - Mizumoto, A
AU - Verwaal, V
AU - Mahtem, H
N1 - Copyright © 2016 Elsevier Ltd. All rights reserved.
PY - 2016/8
Y1 - 2016/8
N2 - Recently, Peritoneal Surface Oncology Group International (PSOGI) developed a novel comprehensive treatment consisting of cytoreductive surgery (CRS) and perioperative chemotherapy (POC) for the treatment of peritoneal metastases (PM) from gastric cancer with curative intent. This article reviews the results of this treatment and verifies its indication. In this strategy, peritoneal cancer index (PCI) is determined by laparoscopy, and a peritoneal port is placed. Neoadjuvant bidirectional intraperitoneal/systemic chemotherapy (NIPS) is performed for 3 cycles, and then laparotomy is performed. Cytoreductive surgery with peritonectomy procedures and hyperthermic intraperitoneal chemoperfusion (HIPEC) are performed. Multivariate analyses showed that completeness of cytoreduction, pathologic response to NIPS and PCI level and cytologic status after NIPS, as independent prognostic factors. PCI less than cut-off level after NIPS, negative cytology after NIPS, and positive response to NIPS were identified as the indications for comprehensive treatment. Patients who hold these criteria should be considered as the candidates for CRS and HIPEC.
AB - Recently, Peritoneal Surface Oncology Group International (PSOGI) developed a novel comprehensive treatment consisting of cytoreductive surgery (CRS) and perioperative chemotherapy (POC) for the treatment of peritoneal metastases (PM) from gastric cancer with curative intent. This article reviews the results of this treatment and verifies its indication. In this strategy, peritoneal cancer index (PCI) is determined by laparoscopy, and a peritoneal port is placed. Neoadjuvant bidirectional intraperitoneal/systemic chemotherapy (NIPS) is performed for 3 cycles, and then laparotomy is performed. Cytoreductive surgery with peritonectomy procedures and hyperthermic intraperitoneal chemoperfusion (HIPEC) are performed. Multivariate analyses showed that completeness of cytoreduction, pathologic response to NIPS and PCI level and cytologic status after NIPS, as independent prognostic factors. PCI less than cut-off level after NIPS, negative cytology after NIPS, and positive response to NIPS were identified as the indications for comprehensive treatment. Patients who hold these criteria should be considered as the candidates for CRS and HIPEC.
KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
KW - Cisplatin/administration & dosage
KW - Cytoreduction Surgical Procedures/methods
KW - Docetaxel
KW - Drug Combinations
KW - Humans
KW - Hyperthermia, Induced/methods
KW - Infusions, Parenteral
KW - Multivariate Analysis
KW - Neoadjuvant Therapy
KW - Oxonic Acid/administration & dosage
KW - Peritoneal Neoplasms/secondary
KW - Peritoneum/surgery
KW - Stomach Neoplasms/pathology
KW - Taxoids/administration & dosage
KW - Tegafur/administration & dosage
U2 - 10.1016/j.ejso.2016.03.016
DO - 10.1016/j.ejso.2016.03.016
M3 - Review article
C2 - 27160355
SN - 1532-2157
VL - 42
SP - 1123
EP - 1131
JO - European Journal of Surgical Oncology
JF - European Journal of Surgical Oncology
IS - 8
ER -
